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Abstract
Several mechanisms have been proposed for the positive health effects associated with dietary consumption of long-chain n-3 PUFA
(n-3 LC-PUFA) including DHA (22 : 6n-3) and EPA (20 : 5n-3). After dietary intake, LC-PUFA are incorporated into membranes and can
be converted to their corresponding N-acylethanolamines (NAE). However, little is known on the biological role of these metabolites.
In the present study, we tested a series of unsaturated NAE on the lipopolysaccharide (LPS)-induced NO production in RAW264.7 macro-
phages. Among the compounds tested, docosahexaenoylethanolamine (DHEA), the ethanolamide of DHA, was found to be the most
potent inhibitor, inducing a dose-dependent inhibition of NO release. Immune-modulating properties of DHEA were further studied in
the same cell line, demonstrating that DHEA significantly suppressed the production of monocyte chemotactic protein-1 (MCP-1), a cyto-
kine playing a pivotal role in chronic inflammation. In LPS-stimulated mouse peritoneal macrophages, DHEA also reduced MCP-1 and NO
production. Furthermore, inhibition was also found to take place at a transcriptional level, as gene expression of MCP-1 and inducible NO
synthase was inhibited by DHEA. To summarise, in the present study, we showed that DHEA, a DHA-derived NAE metabolite, modulates
inflammation by reducing MCP-1 and NO production and expression. These results provide new leads in molecular mechanisms by which
DHA can modulate inflammatory processes.
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Fatty amides formed out of long-chain fatty acids and amino
acids or ethanolamine widely occurr in nature. Increasing
evidence suggests that many of these compounds are import-
ant signalling molecules in plants and animals, mediating a
wide range of biological effects(1–3). The most studied fatty
amide so far is anandamide (arachidonoylethanolamine,
AEA), which is one of the prototypical endogenous mediators
of the endocannabinoid system(4,5). Other fatty amides includ-
ing N-palmitoylethanolamine and N-oleoylethanolamine have
attracted great attention as lipid mediators involved in the
anti-inflammatory processes(6,7) and in the regulation of food
intake(8,9). Also, N-stearoylethanolamine has been reported
to have both anorexic(10) and anti-inflammatory properties(11).
Based on the ubiquitous presence of enzyme systems that are
able to synthesise amides, the hypothesis has been raised that
any available long-chain fatty acid can be amidated with any
amino acid or related compound(5). Indeed, the number of
amides detected in tissues is rapidly increasing(5,12). Probably
several of these ‘novel’ fatty amides might possess bioactivity.
For several fatty amides, it has been demonstrated that
they can be rapidly synthesised from their fatty acid precursors
into membranes, released on demand and quickly broken
down(5,13). Therefore, the local availability of a specific type
of fatty acid precursor may determine product formation and
hence bioactivity. This suggests a link with dietary intake,
since it is well known that incorporation of fatty acids into
membranes can be modulated by their proportional abun-
dance in the diet. From a dietary perspective, n-3 long-chain
PUFA (n-3 LC-PUFA) such as DHA (22 : 6n-3) and EPA
(20 : 5n-3) are of great interest because of their potential
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health-related benefits including a reduction in inflammatory
processes and risks for CVD, type 2 diabetes and, possibly,
certain neurological disorders(14–18). It is well known that
these compounds present in high concentrations in fatty fish
are incorporated into membranes(15) at the expense of that
of arachidonic acid and other fatty acids. Although many
mechanisms have been proposed, hardly anything is known
about the possibility that conversion of n-3 LC-PUFA to fatty
amides, thereby acting as bioactive lipid messengers, plays
a role in these health-inducing effects. Evidence for the
formation of N-acylethanolamines (NAE) from EPA (eicosa-
pentaenoylethanolamine (EPEA)) and DHA (docosahexaenoy-
lethanolamine (DHEA)) in vivo has been published(19–22).
Furthermore, a few publications reporting NAE formation
reveal a direct link between dietary intake of n-3 LC-PUFA
and elevated EPEA and DHEA concentrations in animal
tissues(19,20). Recently, we have demonstrated the formation
of DHEA and EPEA by 3T3 adipocytes from their precursor
fatty acids(23). We have also found that DHEA was abundantly
present in the human plasma of overnight fasted volun-
teers(23). These observations raised further questions concern-
ing the biological functions of DHEA, in particular, in relation
to its immune-modulating effects.
First, a series of chemically closely related NAE, differing
in the chain length and the number of double bonds, was
evaluated for their ability to inhibit NO production by lipopo-
lysaccharide (LPS)-stimulated RAW264.7 macrophages. NO,
produced by inducible NO synthase (iNOS), is a late mediator
induced during conditions of acute and chronic inflammation.
Based on the results obtained, we further studied DHEA,
demonstrating its action on monocyte chemotactic protein-1
(MCP-1), in vitro as well as in mouse peritoneal macrophages.
Additionally, we studied whether DHEA-mediated effects are
exerted at the gene expression level. Overall, the obtained
results provide evidence for a novel molecular pathway med-
iating ‘fish oil’/DHA-associated anti-inflammatory effects.
Methods
Chemicals
Oleoylethanolamine, DEA and AEA were purchased from
Tocris (Bristol, UK). Novozymw435 was from Novozymes
(A/S Bagsvaerd, Denmark). Dulbecco’s modified Eagle’s
medium, Roswell Park Memorial Institute 1640 (RPMI-1640),
fetal bovine serum, streptomycin and penicillin were acquired
from Lonza (Verviers SPRL, Belgium). LPS was obtained from
Sigma-Aldrich (Schnelldorf, Germany). Griess reagents and
nitrite standard were purchased from Cayman Chemical (Ann
Arbor, MI, USA). ELISA was performed using R&D Systems
kits (Abingdon, UK). Bicinchoninic acid (BCA) protein assay
kit was acquired from Pierce (Rockford, IL, USA), and Brewer
thioglycollate was from BD Sciences (Franklin Lakes, NJ, USA).
N-acylethanolamine synthesis
NAE other than DEA, oleoylethanolamine and AEA (see Table 1
for the compounds tested) were prepared from ethanolamine
and their corresponding fatty acids using an enzymatic
procedure as described earlier(24). Briefly, the method is
based on a direct condensation reaction between ethanola-
mine and the fatty acid (molar ratio 1:1), carried out at 408C
in hexane, using Novozymw435 (consisting of immobilised
Candida antarctica Lipase B) as the catalyst. Incubation
times ranged between 8 and 15 h, and product yields obtained
were in the range of 80 and 88 %. Authenticity of the products
was verified by electrospray ionization-MS, 1H NMR, 13C NMR
and Fourier transform infrared(24). Purity of each compound
was more than 98 % as determined by HPLC and NMR.
Cell culture
RAW264.7 macrophages (murine origin) were obtained from
the American Type Culture Collection (Teddington, UK).
RAW264.7 macrophages were grown and maintained in
Dulbecco’s modified Eagle’s medium supplemented with
10 % fetal bovine serum, streptomycin and penicillin at 378C
in a 5 % CO2 humidified air atmosphere. Effects of the test
compounds on the viability of the RAW264.7 cells were
assessed using an XTT Cell Proliferation Kit II (Roche Applied
Science, Almere, The Netherlands) according to the manufac-
turer’s instructions. Briefly, cells were first incubated with the
test compound(s). Thereafter, the tetrazolium salt (ZTT) assay
was performed, where the cells’ ability to metabolise XTT to
formazan was a measure for cell viability. Conditions were
considered toxic if metabolic activity to form formazan was
decreased by .20 %. As a negative control, Triton X100 was
added to the cells, yielding total cell lysis. For further details
on XTT assays, see Lupinacci et al.(25).
Peritoneal macrophages
Male C57Bl/6 mice were injected intraperitoneally with a 4 %
Brewer thioglycollate solution. After 3 d, mice were killed,
and cells in the peritoneal cavity were collected by peritoneal
lavage, using RPMI-1640 medium containing penicillin/
streptomycin. Thereafter, peritoneal macrophages were col-
lected by centrifugation for 5 min at 1250 rpm and 48C, and
pellets were subsequently treated with erythrocyte lysis
Table 1. Names of a series of N-acylethanolamines tested for their
ability to inhibit nitric oxide production
R Acyl chain
Oleoylethanolamine Oleic acid 18 : 1n-9
Linoleoylethanolamine Linoleic acid 18 : 2n-6
Conjugated linoleoylethanolamine Conjugated
linoleic acid
18 : 2
Linolenoylethanolamine Linolenic acid 18 : 3n-3
Arachidonoylethanolamine Arachidonic acid 20 : 4n-6
Eicosapentaenoylethanolamine EPA 20 : 5n-3
Docosatetraenoylethanolamine Docosatetraenoic
acid
22 : 4n-6
Docosahexaenoylethanolamine DHA 22 : 6n-3
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buffer (150 mM-NH4Cl, 10 mM-KHCO3 and 0·1 mM-EDTA) for
5–10 min on ice. Peritoneal macrophages were collected by
centrifugation, and pellets were dissolved in RPMI-1640
containing 10 % heat-inactivated fetal bovine serum and
penicillin/streptomycin. Cells were counted and plated in
a density of approximately 750 000 cells/ml. After 2 h, adher-
ing macrophages were washed with PBS and cultured for
72 h in RPMI-1640 medium (containing 10 % fetal bovine
serum-heat-inactivated and penicillin/streptomycin) before
stimulation.
For these experiments, the institutional and national guide-
lines for the care and use of animals were followed, and
experiments were approved by the Local Committee for
Care and Use of Laboratory Animals at Wageningen University.
Effects of N-acylethanolamines on nitric oxide release,
monocyte chemotactic protein-1 production and inducible
nitric oxide synthase and monocyte chemotactic protein-1
gene expression
RAW264.7 macrophages (2·5 £ 105 cells/ml) were seeded into
ninety-six-well cell culture plates for nitrite, ELISA and cell via-
bility measurements, or into six-well plates (5 £ 105 cells/ml)
for the analysis of mRNA expression, and incubated overnight.
Peritoneal macrophages were isolated and seeded as
described earlier. Adherent cells were pre-incubated for
30 min with the test compound or vehicle in duplicate, after
which LPS, 1mg/ml for RAW264.7, was added in combination
with the same test compound(s). For peritoneal macrophages,
an optimal dose of 0·1mg of LPS stimulation was assessed for
the experimental conditions used. Therefore, peritoneal
macrophages were activated with LPS (0·1mg/ml) to measure
MCP-1 release. However, because of nitrite detection limits,
LPS (1mg/ml) was used to measure NO production. Ethanol
was used (final solvent concentration never exceeded 0·1 %,
v/v) as the solvent. Incubation times were selected based on
the specific properties of different inflammatory mediators.
After incubating for 24 or 48 h, nitrite accumulated in the cul-
ture medium was measured as an indicator of NO production
using the Griess method(26). Briefly, 100ml of the cell culture
medium were mixed with 100ml of Griess reagents and incu-
bated at room temperature for 10 min. Absorbance was
measured at 540 nm using an ELISA plate reader. Following
4 or 16 h incubation, MCP-1 levels were assessed by using
ELISA.
RNA purification and quantitative reverse transcription
real-time PCR
Total RNA was extracted using TRIzolR (Invitrogen, Breda,
The Netherlands). RNA (1mg/sample) was reverse tran-
scribed to give complementary DNA using the reverse tran-
scription system from Promega (Leiden, The Netherlands).
Complementary DNA was amplified by PCR using platinum
Taq DNA polymerase (Invitrogen) and SYBR green
(Molecular Probes, Leiden, The Netherlands) on an iCycler
apparatus (Bio-Rad, Veenendaal, The Netherlands). The fol-
lowing primer pairs were used for amplification of iNOS:
50-GTT-CTC-AGC-CCA-ACA-ATA-CAA-GA-30 (forward) and
50-GTG-GAC-GGG-TCG-ATG-TCA-C-30 (reverse); MCP-1: 50-
CCC-AAT-GAG-TAG-GCT-GGA-GA-30 (forward) and 50-TCT-
GGA-CCC-ATT-CCT-TCT-TG-30 (reverse). Samples were ana-
lysed in duplicate, and mRNA expression levels of the different
genes were normalised to RPS27A2. Primer pairs for RPS27A2
were 50-GGT-TGA-ACC-CTC-GGA-CAC-TA-30 (forward) and
50-GCC-ATC-TTC-CAG-CTG-CTT-AC-30 (reverse).
Statistical analysis
All experiments in RAW264.7 macrophages were performed in
duplicate, and those performed in the peritoneal macrophages
were in triplicate in at least three independent experiments.
Data from all experiments are expressed as percentage of
the LPS-treated controls (set at 100 %). Data are presented as
means and standard errors of the mean (see legends of
the figures). Statistical differences between treatments and
controls were evaluated by two-way ANOVA followed by
Bonferroni’s post hoc test. A P value ,0·05 was considered
as statistically significant. P values were assigned at three
different levels, namely P,0·05, ,0·01 and ,0·001.
Results
Effect of N-acylethanolamines with different chain lengths
and number of double bonds on lipopolysaccharide-
induced nitric oxide production
Fatty acid-derived NAE, chemically closely related to DHEA,
were compared for their immune-modulating properties.
Therefore, a series of NAE differing in chain length (from
C18 to C22) and number of double bonds (1n to 6n) were
tested for their abilities to inhibit LPS-induced nitric oxide pro-
duction in RAW264.7 macrophages. NO is a late inflammatory
marker and can be determined in LPS-stimulated macrophages
from 24 h onwards, with levels still increasing up to 48 h and
possibly later. The effect on NO release was determined at
two time points (24 and 48 h), with concentration dependen-
cies assessed at 48 h. Table 1 shows the molecular structures of
the NAE tested. Oleoylethanolamine and other compounds
having a length of eighteen carbons did not inhibit NO
production either at 24 h (Fig. 1) or at 48 h (Fig. 2). Among
the C20 compounds, AEA did not affect NO levels at
t ¼ 24 h but inhibited NO release at t ¼ 48 h in a slight and
significant way. In contrast, EPEA (20 : 5) and DEA (22 : 4)
significantly decreased NO release at t ¼ 24 h (Fig. 1) and
reduced NO production in a significant way at concentrations
of 1 and 10mM at t ¼ 48 h (Fig. 2). At a concentration of 10mM,
DHEA (22 : 6) significantly suppressed NO production up to
40 % at t ¼ 24 h (Fig. 1) and in a concentration-dependent
way at t ¼ 48 h (Fig. 2). The highest concentration of 10mM
gave a more than 60 % reduction at t ¼ 48, while 1mM
decreased NO production by 20 %. Generally, the potency of
NAE to reduce NO release was enhanced with their increasing
chain length and number of double bonds. The precursor of
DHEA, DHA, produced only little suppression of NO production.
J. Meijerink et al.1800
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Only the highest concentration tested elicited a significant NO
decrease both after 24 and 48 h.
Cell viability was verified using an XTT cell proliferation kit
assay. Neither LPS alone nor LPS in combination with the
highest concentration (10mM) of different NAE affected the
viability of cells after 24 h. At 48 h, cell viability slightly
dropped to a range of 83–87 % but only in the LPS-treated
cells. Cell viability was not further decreased by adding the
tested components, indicating that the observed effect was
caused by LPS. Conditions are regarded toxic if cell viability
lowers more than 20 %. As all the tested compounds were
within the viability range of 83–100 %, experimental con-
ditions were considered non-toxic.
Docosahexaenoylethanolamine elicits dose-dependent
suppression of monocyte chemotactic protein-1
Out of the NAE series, DHEA turned out to be the most effec-
tive component suppressing LPS-induced NO release. These
results prompted us to further focus on DHEA and to investi-
gate its effects on MCP-1, a cytokine playing a pivotal role in
inflammatory processes. In contrast to the late inflammatory
marker nitric oxide, MCP-1 is a relatively early marker of the
LPS-induced inflammatory cascade. MCP-1 production
induced by LPS stimulation in RAW264.7 macrophages is
already observed at 4 h, with levels further increasing to
reach maximum levels at 16 h to stay high until later time
points (J Meijerink, unpublished results). In order to assess
whether DHEA reduces cytokine production also at earlier
time points during the inflammatory cascade, MCP-1 levels
were determined both at 4 h and at 16 h when MCP-1 has
reached maximum levels. Pre-incubation with DHEA dose-
dependently reduced LPS-induced MCP-1 production in
RAW264.7 macrophages both at 4 h (Fig. 3(a)) and at 16 h
(Fig. 3(b)). At 16 h, a significant inhibition of 53 % (P,0·001)
was elicited by 10mM-DHEA, while 100 nM still significantly
evoked a reduction of 18 % (P,0·05). The dose–response
curve at 4 h shows an almost identical curve compared with
the 16 h time point, with the only difference being the lack
of statistical significance for the MCP-1 reduction elicited by
100 nM-DHEA at 4 h. The lowest dose for DHEA-induced
reduction in MCP-1, observed at 16 h, was approximately ten
times lower than the dose needed to reduce NO levels.
Anti-inflammatory effects of docosahexaenoylethanolamine
on mouse peritoneal macrophages
To study whether DHEA exerts similar anti-inflammatory
effects under ex vivo conditions as in vitro, thioglycollate-
elicited peritoneal macrophages were exposed to different
concentrations of DHEA and subsequently activated by LPS.
Pre-incubation with DHEA resulted in diminished levels of
both NO (Fig. 4(a)) and MCP-1 (Fig. 4(b)). A dose-dependent
effect was found for both markers. Due to the limited lifespan
of the primary peritoneal macrophages, NO measurements
were performed at 24 h rather than at 48 h when maximal
levels of production were reached. At the 24 h time point,
10mM-DHEA significantly inhibited NO release up to 47 %
(Fig. 4(a)). Effects are comparable with those exerted in
RAW264.7 cells (Fig. 1). Also, a DHEA-elicited concentration-
dependent effect was found for MCP-1 at 16 h, with the
lowest dose of 1mM being still significant. Effects were less
pronounced as those assessed in RAW264.7 macrophages.
Cell viability of peritoneal macrophages during experimental
conditions was determined using an XTT assay and con-
sidered non-toxic.
Docosahexaenoylethanolamine suppresses
lipopolysaccharide-induced mRNA expression of inducible
nitric oxide synthase and monocyte chemotactic protein-1
In order to investigate whether NO and MCP-1 inhibition
elicited by DHEA is regulated at the gene expression level,
we used quantitative RT-PCR to determine iNOS (Fig. 5(a))
and MCP-1 (Fig. 5(b)) mRNA expression. A concentration of
10mM-DHEA significantly suppressed LPS-induced iNOS
mRNA gene expression at 24 h up to 52 %. A similar dose–
response relationship was found for MCP-1 gene expression,
where the highest dose of DHEA tested resulted in a reduction
of 51 %. Lowest doses eliciting significant reduction were
considerably higher at the gene expression level than at the
production level.
Discussion
Despite the high abundance of nutritionally important n-3
LC-PUFA in brain and other tissues(27–30), remarkably little
has been described so far on their conjugation with amines
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Fig. 1. Efficacy of a series of N-acylethanolamines to inhibit lipopolysacchar-
ide (LPS)-induced nitric oxide release in RAW264.7 macrophages at 24 h.
Efficacies were compared with nitric oxide-reducing effects of the precursor
DHA. All compounds were tested at a dose of 10mM. RAW264.7 macro-
phages were seeded at a density of 250 000 cells/ml and pre-incubated for
30 min with the respective ligands preceding a 24 h LPS (1mg/ml) stimulation,
in the presence of the particular ligand. Protein content of each well was
determined by a bicinchoninic acid assay. Data are expressed as percen-
tage, where LPS stimulation (containing vehicle) was set at 100 %. Average
absolute value for nitrite production with LPS stimulation (control) after 24 h
was approximately 16mM. Values are means of four separate experiments
(each done in duplicate), with standard errors of the mean represented by
vertical bars. Mean values were significantly different from 100 %: **P,0·01,
***P,0·001. OEA, oleoylethanolamine; LEA, linoleoylethanolamine; CLEA,
conjugated linoleoylethanolamine; LNEA, linolenoylethanolamine; AEA, ara-
chidonoylethanolamine; EPEA, eicosapentaenoylethanolamine; DEA, doco-
satetraenoylethanolamine; DHEA, docosahexaenoylethanolamine.
Immune effects of docosahexaenoylethanolamine 1801
B
ri
ti
sh
Jo
u
rn
al
o
f
N
u
tr
it
io
n
120
100
N
O
 p
ro
d
u
ct
io
n
(%
 o
f 
LP
S
 c
o
n
tr
o
l)
80
60
40
20
OEA (µM)
– 0·01 0·1 1 10
LEA (µM)
– 0·01 0·1 1 10
CLEA (µM)
– 0·01 0·1 1 10
LNEA (µM)
– 0·01 0·1 1 10
AEA (µM)
– 0·01 0·1 1 10
EPEA (µM)
– 0·01 0·1 1 10
DEA (µM)
– 0·01 0·1 1 10
DHA (µM)
– 0·01 0·1 1 10
DHEA (µM)
– 0·01 0·1 1 10
0
120
100
N
O
 p
ro
d
u
ct
io
n
(%
 o
f 
LP
S
 c
o
n
tr
o
l)
80
60
40
20
0
120
100
N
O
 p
ro
d
u
ct
io
n
(%
 o
f 
LP
S
 c
o
n
tr
o
l)
80
60
40
20
0
120
100
N
O
 p
ro
d
u
ct
io
n
(%
 o
f 
LP
S
 c
o
n
tr
o
l)
80
60
40
20
0
120
100
N
O
 p
ro
d
u
ct
io
n
(%
 o
f 
LP
S
 c
o
n
tr
o
l)
80
60
40
20
0
120
100
N
O
 p
ro
d
u
ct
io
n
(%
 o
f 
LP
S
 c
o
n
tr
o
l)
80
60
40
20
0
120
100
N
O
 p
ro
d
u
ct
io
n
(%
 o
f 
LP
S
 c
o
n
tr
o
l)
80
60
40
20
0
120
100
N
O
 p
ro
d
u
ct
io
n
(%
 o
f 
LP
S
 c
o
n
tr
o
l)
80
60
40
20
0
120
100
N
O
 p
ro
d
u
ct
io
n
(%
 o
f 
LP
S
 c
o
n
tr
o
l)
80
60
40
20
0
**
***
***
***
***
**
**
*
Fig. 2. Dose–response graphs of lipopolysaccharide (LPS)-induced nitric oxide reduction elicited by a series of N-acylethanolamines and DHA in RAW264.7
macrophages. Compounds were tested in a concentration range of 0·01–10mM. RAW264.7 macrophages were seeded at a density of 250 000 cells/ml and pre-
incubated for 30 min with the respective ligands before a 48 h LPS (1mg/ml) stimulation, in the presence of the particular ligand. The protein content of each well
was determined by a bicinchoninic acid assay. Data are expressed as percentage, where LPS stimulation (containing vehicle) was set at 100 %. Average absolute
value for nitrite production with LPS stimulation (control) after 48 h was approximately 45mM. Values are means of four separate experiments (each done in dupli-
cate), with standard errors of the mean represented by vertical bars. Mean values were significantly different from the control: *P,0·05, **P,0·01, ***P,0·001.
OEA, oleoylethanolamine; LEA, linoleoylethanolamine; CLEA, conjugated linoleoylethanolamine; LNEA, linolenoylethanolamine; AEA, arachidonoylethanolamine;
EPEA, eicosapentaenoylethanolamine; DEA, docosatetraenoylethanolamine; DHEA, docosahexaenoylethanolamine.
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into fatty amides. In addition, hardly anything is known about
the potential biological significance of these amides. About 10
years ago, the presence of DHEA in bovine retina was demon-
strated by Bisogno et al.(21). A few years later, Berger et al.(20)
showed that brain levels of EPEA and DHEA were highly
increased after feeding newborn piglets a milk formula rich
in EPA and DHA. More recently, increased levels of DHEA
and EPEA were demonstrated in the liver and jejunum of
rats that had been fed a high-fish oil diet(19). In a recently pub-
lished study, we showed that DHA can be rapidly and
efficiently converted to its ethanolamide, DHEA, by 3T3-L1
adipocytes(23). This is in accordance with the findings of
Eckardt et al.(22) who demonstrated the presence of DHEA
among other NAE in the culture medium of human primary
pre-adipocytes. In the present study, we investigated the
potential biological implications of these findings and estab-
lished that DHEA, a ‘novel’ bioactive member of the
group of NAE, possesses immune-modulating properties in
macrophages.
Effects on nitric oxide release
NO produced by iNOS has been shown to be a key inflamma-
tory mediator in several diseases associated with the metabolic
syndrome. Disruption of iNOS, by using knockout mice
models, was found to diminish diet-induced atherosclerosis
and improve insulin signalling and glucose tolerance in
obese mice(31–33). NO is a signalling molecule produced in
the oxidative deamination of L-arginine catalysed by a NOS.
During an inflammatory process, the inducible isoform of
this enzyme (iNOS or NOS2), which is not expressed in
non-pathological situations, is up-regulated(34,35). This up-
regulation can be initiated by microbial products such as
LPS, inflammatory cytokines or interferon-g.
Of the NAE tested in the present study, we found that DHEA
had the highest potency to inhibit NO formation in LPS-
stimulated RAW264.7 macrophages. For the C18 chain-length
components, the number and position of double bonds did
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Fig. 3. Effect of docosahexaenoylethanolamine (DHEA) on monocyte chemo-
tactic protein-1 (MCP-1) cytokine production in RAW264.7 macrophages at
different time points. RAW264.7 cells were seeded at a density of 250 000
cells/ml and pre-incubated with a concentration series of DHEA for 30 min
before (a) a 4 h lipopolysaccharide (LPS, 1mg/ml) stimulation in the presence
of DHEA and (b) a 16 h LPS (1mg/ml) stimulation in the presence of DHEA.
The supernatant of the cells was analysed for MCP-1 production by ELISA.
The protein content of each well was determined by a bicinchoninic acid
assay. Values for MCP-1 production were corrected for the amount of protein
for each well separately. Data are expressed as percentage, where LPS
stimulation (containing vehicle) was set at 100 %. Values are means of three
separate experiments (each done in duplicate), with standard errors of the
mean represented by vertical bars. Mean values were significantly different
from the control: *P,0·05, ***P,0·001.
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Fig. 4. Effect of docosahexaenoylethanolamine (DHEA) on monocyte chemo-
tactic protein-1 (MCP-1) cytokine and nitric oxide production in peritoneal
macrophages. Cells were seeded at a density of approximately 750 000
cells/ml and pre-incubated with a concentration series of DHEA 30 min before
(a) a 24 h lipopolysaccharide (LPS, 1mg/ml) stimulation in the presence of
DHEA for nitric oxide determination and (b) a 16 h LPS (0·1mg/ml) stimu-
lation in the presence of DHEA for MCP-1 determination. The supernatant of
the cells was analysed for nitric oxide using the Griess assay and for MCP-1
by ELISA. The protein content of each well was measured by a bicinchoninic
acid assay. Values for MCP-1 and nitric oxide production were corrected
for the amount of protein for each well separately. Data are expressed as
percentage, where LPS stimulation (containing vehicle) was set at 100 %.
Data for nitric oxide represent means of cells isolated from five different mice
(with each biological sample performed in duplicate or triplicate), except for
the doses of 0·1mM-DHEA that was performed in three mice, with standard
errors of the mean represented by vertical bars. For MCP-1 analysis, four
mice were used (with each biological sample performed in duplicate or tripli-
cate). Mean values were significantly different from the control: *P,0·05,
***P,0·001.
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not influence the activity of the fatty amides; none of them
being effective in inhibiting NO release up to a concentration
of 10mM. Increasing the chain length demonstrated that AEA
(20 : 4; anandamide), a well-known endocannabinoid, inhib-
ited NO release at t ¼ 48 h in a slight and significant way.
Further increase in the number of double bonds (20 : 5)
and/or chain length (22 : 4, 22 : 6) led to an increased capacity
to inhibit nitric oxide production, with that of DHEA
(22 : 6n-3) being detectable at a concentration of 0·1mM. Its
precursor DHA only had a small effect in our assay. This
might be in line with results reported by Weldon et al.(36)
who needed relatively high concentrations (100mM) of DHA
and a pre-incubation period to achieve inhibition of the
release of inflammatory mediators in LPS-stimulated THP-1
(human leukaemic monocyte cell line) macrophages. It also
indicates that the effects of DHEA found are not due to its
hydrolysis to DHA, which could occur via fatty acid amide
hydrolase(37). Control studies performed in our group using
LC-MS to assess the stability of DHEA in the experimental
set-up has shown that DHEA concentrations slightly declined
with a 10 % reduction at 2 h to reach an approximately 75 %
decrease after 48 h (M Balvers, unpublished results). This
shows that doses of DHEA were in the active range (.1mM)
during the entire experiment. Moreover, although NO has
been measured at 48 h, data represent DHEA-elicited effects
of a late marker of the inflammatory cascade. It is, however,
very likely that DHEA already exerts its effects early during
the initiation of the cascade. Data for the 4 h time point sup-
port this theory, as DHEA significantly reduced levels of the
relatively early marker MCP-1 at 4 h. Taken together, all data
indicate that the DHEA-elicited immunomodulatory effects
can be explained from the activity of DHEA itself.
Effects of docosahexaenoylethanolamine on monocyte
chemotactic protein-1 protein and mRNA levels
Similar to NO, MCP-1 has been shown to be a key inflamma-
tory mediator in metabolism-related disorders. The pro-
inflammatory chemokine MCP-1 functions as a leucocyte
chemoattractor and is predominantly produced by macro-
phages or endothelial cells. Blocking expression of MCP-1
or its receptor under conditions leading to artherosclerosis
in mice resulted in diminished formation of atherosclerotic
lesions and lipid deposition in their aortas(38,39). Furthermore,
in obesity, a casual relationship for MCP-1 and macrophage
infiltration in adipose tissue, insulin resistance and hepatic
steatosis has been established(40), and only recently, another
study has shown that high levels of circulating MCP-1 in the
plasma are crucial for inducing insulin resistance in mice(41).
We found that DHEA dose-dependently reduced MCP-1
production in both RAW264.7 and thioglycollate-elicited
mouse peritoneal macrophages. The lowest dose at which
DHEA inhibited MCP-1 release was at 100 nM at 16 h in
RAW264.7 cells. Minimum doses eliciting significant reduction
were a factor 100–1000 lower than those reported in the litera-
ture for anti-inflammatory effects mediated by its precursor
DHA or for the n-3 PUFA, EPA(42,43). Interestingly, Shi &
Pestka(44) reported that in peritoneal macrophages of mice,
which were fed a DHA-enriched diet for several weeks, anti-
inflammatory pathways were induced, which were not
found when naive peritoneal macrophages were directly
exposed to DHA. The authors suggest that DHA-derived
metabolites might be responsible for the immune-modulating
effects in vivo rather than DHA itself.
Our data showed that DHEA elicited a suppression of both
MCP-1 and iNOS mRNA. These results suggest that DHEA-
induced inhibition is primarily regulated at the mRNA level.
However, although anti-inflammatory effects at a dose of
10mM reflect inhibition as determined at the protein level,
dose-dependent effects in mRNA expression were only
slightly visible, with 1mM being the lowest dose showing a
small non-significant reduction. Consequently, it cannot be
ruled out that DHEA-elicited effects are regulated by different
mechanisms, with lower doses regulated at the protein level,
while suppressive effects at higher doses are regulated at the
expression level. Alternatively, this discrepancy might also
be caused by differences in relative sensitivity of the tech-
niques used.
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Fig. 5. Effect of docosahexaenoylethanolamine (DHEA) on lipopolysacchar-
ide (LPS)-induced inducible nitric oxide synthase (iNOS) and monocyte
chemotactic protein-1 (MCP-1) mRNA expression at 24 h. RAW264.7 cells
were seeded at a density of 500 000 cells/ml and pre-incubated with a
concentration series of DHEA for 30 min before a 24 h LPS stimulation in the
presence of DHEA. Total RNA was isolated and reverse transcribed to give
complementary DNA before performing quantitative real-time PCR. Details
are described in the Methods section. iNOS and MCP-1 fold increase
normalised to RPS27A2 is expressed as percentage, where LPS stimulation
(without DHEA) was set at 100 %. Values are means of three separate
experiments performed in duplicate, with standard errors represented by
vertical bars. *** Mean value was significantly different from that of the control
(P,0·001).
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n-3 Long-chain PUFA and inflammation: alternative
mechanisms of action
It is well known that eating a diet rich in n-3 LC-PUFA, for
example fatty fish, leads to a gradual incorporation of n-3
LC-PUFA in cellular membranes of different tissues at the
expense of other fatty acids including arachidonic acid(29,45).
This has also been described for cells of the immune
system, causing changes in eicosanoid production patterns
and cellular functionality(14). The fatty acid composition and
positional distribution of dietary TAG have also consequences
for the relative amounts of 2-acylglycerols formed. This
may affect CB1/CB2 receptor binding, either directly (via
sn-2-arachidonoylglycerol) or indirectly, for example via an
‘entourage’ effect. EPA and DHA also serve as precursors for
resolvins, another class of inflammatory mediators(14,15,46).
Resolvins or other DHA eicosanoid products can form novel
N-linked ethanolamines that may be biologically active(4,27).
The formation of amides from n-3 LC-PUFA, as shown in the
present study, might represent a new branch on the tree of
pathways involved in the complex regulation of inflammation.
Endocannabinoid and eicosanoid pathways are known to
share a number of common biotransformation pathways,
regulatory enzymes and, possibly, receptors(47). Local avail-
ability of precursors can play a role in the inflammatory
balance, as has been suggested for n-3 v. n-6 in the
diet(45,48). However, it is also clear that there is not a direct
stoichiometric relationship between dietary intake of precur-
sors and production of inflammatory mediators. Instead, a
well-regulated homeostatic equilibrium exists that fluctuates
between rather narrow boundaries(18,45,46). However, in the
case of endocannabinoids, dietary studies have clearly
shown that this equilibrium is subject to gradual changes.
Although there are only few studies showing direct formation
of NAE from n-3 LC-PUFA precursors, several other studies
have shown that dietary intervention with n-3 fatty acids
also indirectly affects the endocannabinoid balance. For
example, Watanabe et al.(49) have demonstrated that n-3 LC-
PUFA deficiency elevates and n-3 LC-PUFA administration
reduces brain sn-2-arachidonoylglycerol levels in mice. Batetta
et al.(50) have recently shown that diets rich in n-3 LC-PUFA
decreased AEA and sn-2-arachidonoylglycerol levels in the
visceral fat of obese Zucker rats. In the study of Artmann
et al.(19), decreased levels of all NAE measured were found
in the livers of rats fed with n-3 LC-PUFA for 1 week, except
for DHEA and EPEA. However, in the brain, these effects
were not observed, which may be due to the short treatment
period. Taken together, it appears that NAE patterns tend to
follow the relative abundance of lipids in the diet. However,
a few weeks of intake are needed to achieve significant
changes. In addition to stimulating the formation of DHEA
by increasing dietary supply, inhibition of its breakdown
by fatty acid amide hydrolase could further elevate local
concentrations(37). Some NAE, including arachidonoyl seroto-
nin, are known to have fatty acid amide hydrolase-inhibiting
properties(51,52). Hence, NAE that do not bind to CB1 or CB2
can still exert biological action in an indirect way.
Is there a role for docosahexaenoylethanolamine as an
immune modulator?
In relation to the reported health effects of fish oil and n-3 LC-
PUFA, our findings might be of interest for several applications
and areas. One such area is obesity/metabolic syndrome,
where an inflammatory process plays a role(53–56). A
biochemical connection between fish oil intake and the
pathology of obesity has recently been suggested by Batetta
et al.(50), showing that n-3 LC-PUFA supplementation inhibited
the inflammatory process and ectopic fat deposition while
reducing AEA in obese Zucker rats. Several studies have
demonstrated the importance of NO in obesity and the
metabolic syndrome(57–60). Fish oil has also shown potential
beneficial activity in inflammatory diseases of the intestinal
tract(61), and high incorporation of DHEA and EPEA was
found in gut tissue after a fish oil diet(19). In conclusion, our
data provide evidence for a novel mechanism by which
DHA exerts immune-modulating effects, namely as a precur-
sor of DHEA. Combined with findings from previous studies,
our data provide new viewpoints on the relationship between
dietary intake of DHA and local inflammatory processes. It
is tempting to speculate that DHEA might possibly play a
significant role in inflammatory processes in vivo, thereby
functioning as an endogenous ‘natural’ ligand. Further studies
should elucidate the relevance of this ‘fish oil messenger’
in vivo and the relationship to other inflammatory pathways
in which DHA is involved.
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